Patents by Inventor Dan H. Schulze

Dan H. Schulze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20210277091
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 9, 2021
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • Immunoglobulin constant region Fc receptor binding agents
    Patent number: 10941191
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 9, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, GLIKNIK INC.
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Immunoglobulin constant region Fc receptor binding agents
    Patent number: 10851154
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: December 1, 2020
    Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20190218275
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 18, 2019
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • Immunoglobulin constant region Fc receptor binding agents
    Patent number: 10208105
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 19, 2019
    Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20180186862
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • Immunoglobulin constant region Fc receptor binding agents
    Patent number: 9926362
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: March 27, 2018
    Assignees: Gliknik Inc., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20170218049
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.
    Type: Application
    Filed: April 10, 2017
    Publication date: August 3, 2017
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20160355570
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 8, 2016
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Immunoglobulin constant region FC receptor binding agents
    Patent number: 9512208
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: December 6, 2016
    Assignees: GLIKNIK INC., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Immunoglobulin constant region Fc receptor binding agents
    Patent number: 9512210
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: December 6, 2016
    Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20160280768
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20150056185
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 20, 2014
    Publication date: February 26, 2015
    Applicants: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20140335075
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 13, 2014
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20140105913
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: September 20, 2013
    Publication date: April 17, 2014
    Applicants: GLIKNIK, INC., University of Maryland, Baltimore
    Inventors: Scott E. STROME, Dan H. Schulze, David S. Block
  • Immunoglobulin constant region FC receptor binding agents
    Patent number: 8680237
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 25, 2014
    Assignees: Gliknik Inc., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20120309941
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 6, 2012
    Applicants: GLIKNIK, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20100239633
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 30, 2008
    Publication date: September 23, 2010
    Applicant: UNIVERSITY OF MARYLAND BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block